Replies to post #126139 on Biotech Values

[DewDiligence]

Perhaps this puts ANDS' setrobuvir (aka ANA598) in play now. (I'm being entirely facetious of course.) ; )

In all seriousness, the non-nuke class has been a gigantic black hole for developers. Although the non-nuke programs from ANDS, GILD, IDIX, VPHM, and VRTX have gone nowhere, several other companies (ABT, B-I, MRK, PFE) are still trying.

[DewDiligence]

ANDS reports 28-day (EVR) data in phase-2b trial of Setrobuvir (f/k/a ANA598):

http://finance.yahoo.com/news/Anadys-Announces-Positive-prnews-3498931386.html?x=0&.v=1

So far, so good, but EVR data per se don’t mean much. To date, no one has come forward to partner with ANDS on this drug, which belongs to the non-nuke class that has produced several notable duds (#msg-66814203).